Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 11, 2010 - Issue 12
Submit an article Journal homepage
415
Views
19
CrossRef citations to date
0
Altmetric
Reviews

Differences between long-acting insulins for the treatment of type 2 diabetes

Michael Gejl Jensen Aarhus University, Department of Pharmacology, Wilh. Meyers Alle, Bldn. 1242, DK-8000, Aarhus C, Denmark +4589491708; +4586129904; [email protected]
, MD,
Mikkel Hansen Sanofi-aventis DK, Medical Department, Slotsmarken 13, DK-2970, Hørsholm, Denmark
, MD,
Birgitte Brock Aarhus University, Department of Pharmacology, Wilh. Meyers Alle, Bldn. 1242, DK-8000, Aarhus C, Denmark +4589491708; +4586129904; [email protected]
, MD PhD &
Jørgen Rungby Aarhus University, Department of Pharmacology, Wilh. Meyers Alle, Bldn. 1242, DK-8000, Aarhus C, Denmark +4589491708; +4586129904; [email protected]
, MD DMSc
Pages 2027-2035 | Published online: 19 Jul 2010

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Stuart A. Ross, Hugh D. Tildesley & John Ashkenas. (2011) Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Current Medical Research and Opinion 27:sup3, pages 13-20.
Read now
Nicolás Prados, Antonio Pellicer & Manuel Fernandez-Sanchez. (2011) Corifollitropin alfa: a new recombinant FSH gonadotropin analog. Expert Review of Obstetrics & Gynecology 6:4, pages 395-402.
Read now
Anne-Laure Guillermin, Yevgeniy Samyshkin, Donna Wright, Tini Nguyen & Julie Villeneuve. (2011) Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. Journal of Medical Economics 14:2, pages 207-216.
Read now

Articles from other publishers (16)

Thomas Semlitsch, Jennifer Engler, Andrea Siebenhofer, Klaus Jeitler, Andrea Berghold & Karl Horvath. (2020) (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2020:11.
Crossref
Rebecca S. Holmes, Elizabeth Crabtree & Marian S. McDonagh. (2019) Comparative effectiveness and harms of long‐acting insulins for type 1 and type 2 diabetes: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 21:4, pages 984-992.
Crossref
Saleh Adi & Andrea Gerard-Gonzalez. 2018. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome 3 13 .
I. B. Hirsch, E. Franek, H. Mersebach, L. Bardtrum & K. Hermansen. (2017) Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST ® T1) . Diabetic Medicine 34:2, pages 167-173.
Crossref
Unchalee Permsuwan, Nathorn Chaiyakunapruk, Piyameth Dilokthornsakul, Kednapa Thavorn & Surasak Saokaew. (2016) Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand. Applied Health Economics and Health Policy 14:3, pages 281-292.
Crossref
Monika Lechleitner, Michael Roden, Raimund Weitgasser, Bernhard Ludvik, Peter Fasching, Friedrich Hoppichler, Alexandra Kautzky-Willer, Guntram Schernthaner, Rudolf Prager & Thomas C. Wascher. (2016) Insulintherapie bei Diabetes mellitusInsulin therapy of diabetes. Wiener klinische Wochenschrift 128:S2, pages 54-61.
Crossref
S. J. Jacober, J. Rosenstock, R. M. Bergenstal, M. J. Prince, Y. Qu & J. M. Beals. (2014) Contrasting weight changes with LY2605541, a novel long-acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM. Diabetes, Obesity and Metabolism 16:4, pages 351-356.
Crossref
R. G. Josse & V. Woo. (2013) Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin. Diabetes, Obesity and Metabolism 15:12, pages 1077-1084.
Crossref
Chantal Mathieu. (2013) How long should a long acting insulin analogue be?. Diabetes Research and Clinical Practice 100:2, pages 170-172.
Crossref
J. J. Holst & T. Vilsbøll. (2013) Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes, Obesity and Metabolism 15:1, pages 3-14.
Crossref
Monika Lechleitner, Michael Roden, Raimund Weitgasser, Bernhard Ludvik, Peter Fasching, Friedrich Hoppichler, Alexandra Kautzky-Willer, Guntram Schernthaner, Rudolf Prager & T. C. Wascher. (2012) Insulintherapie bei Diabetes mellitusInsulin therapy of diabetes. Wiener klinische Wochenschrift 124:S2, pages 17-22.
Crossref
Irl B. Hirsch, Bruce Bode, Jean-Pierre Courreges, Patrik Dykiel, Edward Franek, Kjeld Hermansen, Allen King, Henriette Mersebach & Melanie Davies. (2012) Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes. Diabetes Care 35:11, pages 2174-2181.
Crossref
Anastasia N. Mavrogiannaki & Ilias N. Migdalis. (2012) Long-acting basal insulin analogs: latest developments and clinical usefulness. Therapeutic Advances in Chronic Disease 3:6, pages 249-257.
Crossref
Andrea Gerard Gonzalez & Saleh Adi. 2012. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome 3 13 .
Johannes Winkler. (2011) Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Therapeutic Delivery 2:7, pages 891-905.
Crossref
Monika Lechleitner & Friedrich Hoppichler. (2011) Insulin therapyInsulintherapie. Wiener Medizinische Wochenschrift 161:11-12, pages 300-304.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.